Sumitomo Pharma Co., Ltd. (TYO:4506)
Japan
· Delayed Price · Currency is JPY 2,441.00
+5.50 (0.23%)
At close: Dec 5, 2025
Sumitomo Pharma Revenue
Sumitomo Pharma had revenue of 119.12B JPY in the quarter ending September 30, 2025, with 32.25% growth. This brings the company's revenue in the last twelve months to 445.21B, up 29.92% year-over-year. In the fiscal year ending March 31, 2025, Sumitomo Pharma had annual revenue of 398.83B with 26.79% growth.
Revenue (ttm)
445.21B
Revenue Growth
+29.92%
P/S Ratio
2.18
Revenue / Employee
116.18M
Employees
3,832
Market Cap
969.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 398.83B | 84.27B | 26.79% |
| Mar 31, 2024 | 314.56B | -240.99B | -43.38% |
| Mar 31, 2023 | 555.54B | -4.49B | -0.80% |
| Mar 31, 2022 | 560.04B | 44.08B | 8.54% |
| Mar 31, 2021 | 515.95B | 33.22B | 6.88% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,213.71B |
| HOYA Corporation | 892.50B |
| Takeda Pharmaceutical Company | 4,417.00B |
| Daiichi Sankyo Company | 1,978.88B |
| Otsuka Holdings | 2,418.53B |
| Astellas Pharma | 2,006.82B |
| Terumo | 1,062.42B |
| Shionogi & | 437.26B |